Yinchenhao decoction adjustment for treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials

Aim. To assess the efficacy of berberine in the treatment of nonalcoholic fatty liver disease through meta-analysis.Method. We searched Embase, Pubmed, Cochrane Library, and so forth, until March 2016 for randomized controlled trials using berberine to treat NAFLD.Result. Six randomized controlled trials involving 501 patients were included in this study. The results showed that the efficacy of reducing TC, LDL, ALT, 2hPG, and HbA1c in NAFLD patients of the berberine group were significantly higher than that of control group. The subgroup analyses on TG, AST, and FBG indicated that treatment combined with berberine decreased TG level in NAFLD patients significantly. Compared with other drugs, berberine alone decreased TG level in NAFLD patients significantly. We also conducted a descriptive analysis on insulin resistance and radiography results that berberine can improve NAFLD patients’ insulin resistance and fatty liver.Conclusion. According to analysis result, berberine has positive efficacy on blood lipids, blood glucose, liver function, insulin resistance, and fatty liver condition of NAFLD patients. However, due to the limitation of number and quality of trials included, more clinical randomized controlled trials with high quality are needed for further verification of the efficacy of berberine on NAFLD patients.

Download Full-text

Effect of Nigella sativa in the treatment of nonalcoholic fatty liver disease: A systematic review and meta‐analysis of randomized controlled trials

Phytotherapy Research ◽

10.1002/ptr.7080 ◽

2021 ◽

Author(s):

Gang Tang ◽

Linyu Zhang ◽

Jie Tao ◽

Zhengqiang Wei

Keyword(s):

Systematic Review ◽

Liver Disease ◽

Fatty Liver ◽

Randomized Controlled Trials ◽

Fatty Liver Disease ◽

Nigella Sativa ◽

Meta Analysis ◽

Controlled Trials ◽

Nonalcoholic Fatty Liver ◽

Randomized Controlled

Download Full-text

Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials

Nutrition ◽

10.1016/j.nut.2014.11.018 ◽

2015 ◽

Vol 31 (7-8) ◽

pp. 923-930 ◽

Cited By ~ 73

Author(s):

Ken Sato ◽

Masahiko Gosho ◽

Takaya Yamamoto ◽

Yuji Kobayashi ◽

Norimitsu Ishii ◽

...

Keyword(s):

Liver Disease ◽

Vitamin E ◽

Beneficial Effect ◽

Fatty Liver ◽

Randomized Controlled Trials ◽

Fatty Liver Disease ◽

Meta Analysis ◽

Controlled Trials ◽

Nonalcoholic Fatty Liver ◽

Randomized Controlled

Download Full-text

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Metabolites ◽

10.3390/metabo11020073 ◽

2021 ◽

Vol 11 (2) ◽

pp. 73

Author(s):

Alessandro Mantovani ◽

Graziana Petracca ◽

Giorgia Beatrice ◽

Alessandro Csermely ◽

Amedeo Lonardo ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Randomized Controlled Trials ◽

Fatty Liver Disease ◽

Meta Analysis ◽

Controlled Trials ◽

Nonalcoholic Fatty Liver ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide (n = 6 RCTs), exenatide (n = 3 RCTs), dulaglutide (n = 1 RCT) or semaglutide (n = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy (n = 2 RCTs) or imaging techniques (n = 9 RCTs). Compared to placebo or reference therapy, treatment with GLP-1 RAs for a median of 26 weeks was associated with significant reductions in the absolute percentage of liver fat content on magnetic resonance-based techniques (pooled weighted mean difference: −3.92%, 95% confidence intervals (CI) −6.27% to −1.56%) and serum liver enzyme levels, as well as with greater histological resolution of NASH without worsening of liver fibrosis (pooled random-effects odds ratio 4.06, 95% CI 2.52–6.55; for liraglutide and semaglutide only). In conclusion, treatment with GLP-1 RAs (mostly liraglutide and semaglutide) is a promising treatment option for NAFLD or NASH that warrants further investigation.

Download Full-text